$ANVS News

Annovis Bio Prices Underwritten Public Offering Of 7,895,000 Shares And Warrants To Purchase Up To 7,105,500 Shares At $1.90 Per Unit

Annovis Bio Q1 EPS $(0.63) Misses $(0.40) Estimate

Annovis Bio Announces New Publication Titled Buntanetap Treatment In Mild To Moderate Alzheimer's Disease: Phase 2/3 Study In Peer-Reviewed Journal Nature NPJ Dementia

Annovis Bio Closes Underwritten Public Offering Raising ~$10M In Gross Proceeds; Financing Secures Path To First NDA Submission For Buntanetap

Annovis Bio (ANVS) Price Target Increased by 13.94% to 15.98

Annovis Bio shares are trading lower after the company announced pricing of its $10 million offering of common stock and warrants.

Annovis Bio shares are trading lower after the company announced pricing of its $10 million offering of common stock and warrants.

Annovis Bio Prices Underwritten Offering Of 5.3m Shares And Warrants At $1.90 Per Unit

Annovis Bio shares are trading higher after a Form 4 filing showed that a Director purchased 713,800 shares at $2.10 per share.

Annovis Secures U.S. Patent for Buntanetap in the Prevention and Treatment of Neurological Injuries Caused by Brain Infections

Annovis Bio Issued New U.S. Patent For Prevention And Treatment Of Neurological Injuries From Brain Infections

Annovis Publishes Historical Review of Buntanetap in The Scientist

Annovis Bio Mark Guerin Steps Down As CFO Effective March 23, 2026; CEO Maria Maccecchini To Serve As Acting CFO Until Replacement Is Identified

NeuroRPM to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical Trial

Annovis Partners with NeuroRPM to Deploy AI-Powered Digital Biomarker Technology in Parkinson's Disease Study

NeuroRPM's Wearable Platform To Be Used For Digital Biomarker Monitoring In Annovis Bio's ANVS-25002 Open-Label Parkinson's Disease Clinical Study

Annovis Bio shares are trading higher. The company reported Q4 financial results.

Annovis Provides Corporate Updates and Reports Fiscal Year 2025 Financial Results

Annovis Bio Q4 EPS $(0.39) Misses $(0.34) Estimate

Annovis Announces Two Presentations at the AD/PD™ 2026 International Conference